Article
Biochemistry & Molecular Biology
Zheng Wang, Lijun Wen, Ling Zhang, Xiaoyu Xu, Xiaoqian Chen, Li Yao, Man Wang, Zhen Shen, Guangquan Mo, Yao Wang, Dewan Zhao, Wei Cai, Jingzhi Shen, Xiaomeng Chi, Yi Xu, Zhao Zeng, Jinlan Pan, Changgeng Ruan, Depei Wu, Zhilin Jia, Suning Chen
Summary: Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by the PML-RARA fusion gene. A novel RARA fusion, TNRC18-RARA, was identified in APL cases similar to classic APL. This study emphasizes the importance of utilizing multiple molecular techniques to characterize and effectively manage APL without the classic PML-RARA fusion.
MOLECULAR CARCINOGENESIS
(2021)
Article
Multidisciplinary Sciences
William Villiers, Audrey Kelly, Xiaohan He, James Kaufman-Cook, Abdurrahman Elbasir, Halima Bensmail, Paul Lavender, Richard Dillon, Borbala Mifsud, Cameron S. Osborne
Summary: The PML-RARA gene fusion is the characteristic driver of Acute Promyelocytic Leukaemia (APL) and is known to bind to the genome. Here, the authors characterise the impact of PML-RARA on gene regulation in APL cell lines and patient samples using transcriptomics, epigenomics, and machine learning.
NATURE COMMUNICATIONS
(2023)
Letter
Oncology
Xubo Gong, Piaoping Kong, Teng Yu, Xibin Xiao, Lin Wang, Yiwen Sang, Xiang Li, Bin Zhang, Zhihua Tao, Weiwei Liu
Summary: This study reported a case of atypical APL patient with slow disease progression over nearly 2 years without anti-leukemia therapy. The results showed that anti-HBV drugs ADV and ETV exhibited significant inhibitory effects on APL cells, with ADV demonstrating stronger cytotoxicity. ADV also promoted APL cell differentiation and apoptosis, thereby restraining the progression of APL. The study uncovered a novel mechanism of ADV prohibiting APL progression by inhibiting TRIB3 and degrading PML-RARA.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Bong Kyun Kim, Sang-A Lee, Minju Park, Eui Ju Jeon, Mi Jung Kim, Jung Min Kim, Heesuk Kim, Seungwon Jung, Sang Kyung Kim
Summary: This article introduces a photonic PCR platform using hydrogel microparticles, which utilizes photothermal nanomaterials as heating elements for rapid and portable POCT. The researchers successfully demonstrate the ability to perform multiplex assays by loading multiple encoded pPIN microparticles in a single reaction.
Article
Oncology
Marie-France Gagnon, Holly E. Berg, Reid G. Meyer, William R. Sukov, Daniel L. Van Dyke, Robert B. Jenkins, Patricia T. Greipp, Erik C. Thorland, Nicole L. Hoppman, Xinjie Xu, Linda B. Baughn, Kaaren K. Reichard, Rhett P. Ketterling, Jess F. Peterson
Summary: This study evaluated the genetic findings of 831 cases with APL and found that atypical genetic mechanisms leading to the oncogenic PML::RARA fusion exist in some cases. Additionally, other chromosome abnormalities were observed in some cases. These findings provide important information for APL research in both clinical and research laboratory settings.
GENES CHROMOSOMES & CANCER
(2022)
Article
Biochemistry & Molecular Biology
Xinping Huang, Yongfeng Yang, Dan Zhu, Yan Zhao, Min Wei, Ke Li, Hong-Hu Zhu, Xiaofeng Zheng
Summary: The research reveals that PRMT5 is highly expressed in APL patients and promotes APL by interacting with PML-RAR alpha. Inhibition of PRMT5 effectively blocks the growth of APL cells, and combined use with As2O3 shows promise as a therapeutic strategy against APL.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2022)
Article
Hematology
Calogero Lauricella, Rosa Greco, Valentina Mancini, Valentina Motta, Anna Ciraolo, Gabriella De Canal, Elena De Paoli, Giulia Paglino, Valentina Guido, Emanuela Bonoldi, Silvio Veronese, Silvia Soriani
Summary: The majority of patients with acute promyelocytic leukemia (APL) have a specific genetic translocation t(15;17)(q24;21), but this case report describes a rare variant of the PML::RARA fusion gene. However, the patient achieved complete remission after standard treatment, suggesting that this atypical variant does not affect the effectiveness of combined therapy with ATRA and ATO.
ACTA HAEMATOLOGICA
(2022)
Article
Medicine, Research & Experimental
Wenran Dan, Liang Zhong, Lihua Yu, Ling Xiong, Jian Li, Jiao Ye, Xu Luo, Chen Liu, Xuan Chu, Beizhong Liu
Summary: This study investigates the role of Skp2 and JunB in the progression of acute promyelocytic leukemia (APL) and the related mechanisms. The results show that elevated Skp2 expression promotes APL progression by decreasing the expression of lncRNA HOTAIRM1 and inhibiting GSK3β, leading to autophagy inhibition and the suppression of PML-RARα ubiquitylation and degradation. This represses JunB transcriptional activation through the PU.1/PML-RARα transcriptional complex, blocking cell differentiation. Inhibition of Skp2 induces JunB expression and contributes to the eradication of APL by accelerating the degradation of PML-RARα. The expressions of Skp2 and JunB are negatively correlated in mice subcutaneous leukemia xenograft tumors.
Article
Environmental Sciences
Guo Bo, Qin Ran, Chen Ji Jun, Pan Wen, Lu Xue Chun
Summary: The dysregulated expression of miR-125b is actively involved in the progression and pathophysiology of acute promyelocytic leukemia. Targeting miR-125b may represent a new therapeutic option for this type of leukemia.
BIOMEDICAL AND ENVIRONMENTAL SCIENCES
(2022)
Article
Multidisciplinary Sciences
Walid Hossain, Mohabbat Hossain, Khalid Arafath, Subarna Sayed Ety, Mahade Hasan Shetu, Mazbahul Kabir, Farjana Akther Noor, Kalissar Mannoor
Summary: The study aimed to reduce the run time of multiplex RT-PCR for detecting SARS CoV-2 N1 and N2 sequences and human RNase P (RP) sequence. By optimizing the Fast PCR protocol and comparing it with conventional PCR, the researchers found that Fast PCR significantly shortened the run time while yielding comparable results to conventional PCR.
Review
Oncology
Luca Guarnera, Tiziana Ottone, Emiliano Fabiani, Mariadomenica Divona, Arianna Savi, Serena Travaglini, Giulia Falconi, Paola Panetta, Maria Cristina Rapanotti, Maria Teresa Voso
Summary: APL, a subtype of AML, has a favorable prognosis thanks to ATRA and ATO combination therapy, but some cases caused by atypical transcripts have variable response rates to treatment, posing a challenge for clinical management.
FRONTIERS IN ONCOLOGY
(2022)
Article
Chemistry, Analytical
Yuwei Qiu, Kunlun Jiang, Jingrui Wu, Yung-Kang Peng, Jeong-Wook Oh, Jung- Hoon Lee
Summary: A plasmonic photothermal quantitative immuno-PCR (PPT-qiPCR) assay is developed for biomarker detection using multifunctional plasmonic immunomagnetic nanoparticles (PIMNs). This assay has real-time and end-point dual readout and is simple, time-saving, and inexpensive compared to conventional iPCR platforms. It can quickly discriminate target proteins and improve assay sensitivity with in-situ end-point fluorescence or colorimetric detection using only the human eye.
SENSORS AND ACTUATORS B-CHEMICAL
(2023)
Article
Agriculture, Multidisciplinary
Song Xiang-peng, Xia Ying-ju, Xu Lu, Zhao Jun-jie, Wang Zhen, Zhao Qi-zu, Liu Ye-bing, Zhang Qian-yi, Wang Qin
Summary: With the implementation of the C-strain vaccine, classical swine fever (CSF) has been controlled in China, while African swine fever (ASF) and atypical porcine pestivirus (APPV) still pose challenges to the pig industry. It is crucial to develop a reliable method for simultaneous detection and differential diagnosis of these diseases. In this study, a multiplex real-time PCR assay was established, which showed high sensitivity and specificity for the detection of CSFV, ASFV, and APPV.
JOURNAL OF INTEGRATIVE AGRICULTURE
(2023)
Article
Chemistry, Multidisciplinary
Jing Tu, Yi Qiao, Yuhan Luo, Naiyun Long, Zuhong Lu
Summary: DNA quantification is crucial in life sciences research, and real-time MDA technology can provide template amount information during whole-genome amplification with a very low detection limit, offering a promising tool to quantify entire DNA without sacrificing sample completeness or introducing redundant steps.
Article
Chemistry, Multidisciplinary
Byoung-Hoon Kang, Youngseop Lee, Eun-Sil Yu, Hamin Na, Minhee Kang, Hee Jae Huh, Ki-Hun Jeong
Summary: The rapid and accurate molecular diagnostics are crucial in the face of pandemic diseases, and the nanoplasmonic PCR provides a new solution for rapid and quantitative molecular diagnostics at point-of-care level.
Article
Oncology
Frank G. Rucker, Ling Du, Tamara J. Luck, Axel Benner, Julia Krzykalla, Insa Gathmann, Maria Teresa Voso, Sergio Amadori, Thomas W. Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Lynn Savoie, Jorge Sierra, Celine Pallaud, Miguel A. Sanz, Joop H. Jansen, Dietger Niederwieser, Thomas Fischer, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Lars Bullinger, Richard A. Larson, Clara D. Bloomfield, Richard M. Stone, Hartmut Doehner, Christian Thiede, Konstanze Doehner
Summary: In AML, internal tandem duplications of the FLT3 gene are associated with poor prognosis. Specifically, insertion site in TKD1 is correlated with unfavorable prognosis, and treatment with Midostaurin does not improve this condition.
Article
Oncology
Natalia Cenfra, Gianfranco Lapietra, Salvatore Perrone, Maria Teresa Voso, Mariadomenica Divona, Sergio Mecarocci, Elettra Ortu La Barbera, Giuseppe Cimino
Summary: Although recent discoveries have advanced understanding of the molecular landscape of acute myeloid leukemia, treating elderly and unfit young patients remains challenging. In these cases, hypomethylating agents may still be an effective therapeutic option.
Editorial Material
Pharmacology & Pharmacy
Carmelo Gurnari, Mariadomenica Divona, Maria Teresa Voso
EXPERT OPINION ON PHARMACOTHERAPY
(2022)
Letter
Oncology
Raffaele Palmieri, Francesco Buccisano, Valentina Arena, Maria Antonietta Irno Consalvo, Alfonso Piciocchi, Luca Maurillo, Maria Ilaria DelPrincipe, Ambra Di Veroli, Giovangiacinto Paterno, Consuelo Conti, Daniela Fraboni, Maria Teresa Voso, William Arcese, Adriano Venditti
LEUKEMIA & LYMPHOMA
(2022)
Correction
Multidisciplinary Sciences
Wei-Yu Lin, Sarah E. Fordham, Eric Hungate, Nicola J. Sunter, Claire Elstob, Yaobo Xu, Catherine Park, Anne Quante, Konstantin Strauch, Christian Gieger, Andrew Skol, Thahira Rahman, Lara Sucheston-Campbell, Junke Wang, Theresa Hahn, Alyssa I. Clay-Gilmour, Gail L. Jones, Helen J. Marr, Graham H. Jackson, Tobias Menne, Mathew Collin, Adam Ivey, Robert K. Hills, Alan K. Burnett, Nigel H. Russell, Jude Fitzgibbon, Richard A. Larson, Michelle M. Le Beau, Wendy Stock, Olaf Heidenreich, Abrar Alharbi, David J. Allsup, Richard S. Houlston, Jean Norden, Anne M. Dickinson, Elisabeth Douglas, Clare Lendrem, Ann K. Daly, Louise Palm, Kim Piechocki, Sally Jeffries, Martin Bornhauser, Christoph Rollig, Heidi Altmann, Leo Ruhnke, Desiree Kunadt, Lisa Wagenfuhr, Heather J. Cordell, Rebecca Darlay, Mette K. Andersen, Maria C. Fontana, Giovanni Martinelli, Giovanni Marconi, Miguel A. Sanz, Jose Cervera, Ines Gomez-Segui, Thomas Cluzeau, Chimene Moreilhon, Sophie Raynaud, Heinz Sill, Maria Teresa Voso, Francesco Lo-Coco, Herve Dombret, Meyling Cheok, Claude Preudhomme, Rosemary E. Gale, David Linch, Julia Gaal-Wesinger, Andras Masszi, Daniel Nowak, Wolf-Karsten Hofmann, Amanda Gilkes, Kimmo Porkka, Jelena D. Milosevic Feenstra, Robert Kralovics, David Grimwade, Manja Meggendorfer, Torsten Haferlach, Szilvia Krizsan, Csaba Bodor, Friedrich Stolzel, Kenan Onel, James M. Allan
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Elena Genovese, Margherita Mirabile, Sebastiano Rontauroli, Stefano Sartini, Sebastian Fantini, Lara Tavernari, Monica Maccaferri, Paola Guglielmelli, Elisa Bianchi, Sandra Parenti, Chiara Carretta, Selene Mallia, Sara Castellano, Corrado Colasante, Manjola Balliu, Niccolo Bartalucci, Raffaele Palmieri, Tiziana Ottone, Barbara Mora, Leonardo Potenza, Francesco Passamonti, Maria Teresa Voso, Mario Luppi, Alessandro Maria Vannucchi, Enrico Tagliafico, Rossella Manfredini
Summary: Myelofibrosis is a type of myeloproliferative neoplasm with poor prognosis and no response to traditional therapies. Driver mutations in JAK2 and CALR impact ROS production and oxidative DNA damage, with CALR-mutated patients showing higher ROS levels and lower antioxidant activity compared to JAK2-mutated patients. High plasma levels of total antioxidant capacity are associated with adverse clinical features and poor overall survival, particularly in patients with JAK2 mutations, suggesting a different response to oxidative stress as a potential mechanism underlying myelofibrosis progression.
Article
Hematology
Francesco Buccisano, Raffaele Palmieri, Alfonso Piciocchi, Valentina Arena, Anna Candoni, Lorella Melillo, Valeria Calafiore, Roberto Cairoli, Paolo de Fabritiis, Gabriella Storti, Prassede Salutari, Francesco Lanza, Giovanni Martinelli, Mario Luppi, Saveria Capria, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Maria Antonietta Irno Consalvo, Tiziana Ottone, Serena Lavorgna, Maria Teresa Voso, Paola Fazi, Marco Vignetti, William Arcese, Adriano Venditti
Summary: Based on the post hoc analysis of the GIMEMA AML1310 trial, the ELN2017 classification accurately discriminates patients with acute myeloid leukemia and can guide different transplant strategies.
Article
Hematology
Maria-Teresa Voso, Tatjana Pandzic, Giulia Falconi, Marija Dencic-Fekete, Eleonora De Bellis, Lydia Scarfo, Viktor Ljungstrom, Michail Iskas, Giovanni Del Poeta, Pamela Ranghetti, Stamatia Laidou, Antonio Cristiano, Karla Plevova, Silvia Imbergamo, Marie Engvall, Antonella Zucchetto, Chiara Salvetti, Francesca R. Mauro, Niki Stavroyianni, Lucia Cavelier, Paolo Ghia, Kostas Stamatopoulos, Emiliano Fabiani, Panagiotis Baliakas
Summary: This study confirms the potential impact of clonal hematopoiesis of indeterminate potential (CHIP) on the development of therapy-related myeloid neoplasms (t-MN) in patients with chronic lymphocytic leukemia (CLL). The findings suggest a significantly higher prevalence of CHIP in CLL patients who develop t-MN compared to the general CLL population.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Editorial Material
Hematology
Maria Teresa Voso, Francesco Buccisano
Summary: In this study, Li et al demonstrate that detection of leukemic stem cells (LSCs) using multiparameter flow cytometry (MFC) may be a better predictor of relapse and overall survival (OS) after allogeneic hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) compared to classical measurable residual disease (MRD).
Article
Oncology
Monica Messina, Alfonso Piciocchi, Tiziana Ottone, Stefania Paolini, Cristina Papayannidis, Federica Lessi, Nicola Stefano Fracchiolla, Fabio Forghieri, Anna Candoni, Andrea Mengarelli, Maria Paola Martelli, Adriano Venditti, Angelo Michele Carella, Francesco Albano, Valentina Mancini, Bernardi Massimo, Valentina Arena, Valeria Sargentini, Mariarita Sciume, Domenico Pastore, Elisabetta Todisco, Giovanni Roti, Sergio Siragusa, Marco Ladetto, Stefano Pravato, Eleonora De Bellis, Giorgia Simonetti, Giovanni Marconi, Claudio Cerchione, Paola Fazi, Marco Vignetti, Sergio Amadori, Giovanni Martinelli, Maria Teresa Voso
Summary: IDH1/2 mutations are common in acute myeloid leukemia (AML) and represent a therapeutic target. The GIMEMA AML1516 observational protocol confirms that IDH1/2 mutations are frequently detected at diagnosis and emphasizes the importance of recognizing IDH1/2-mutated cases up-front to offer the most appropriate therapeutic strategy, given the availability of IDH1/2 inhibitors. In the subset of IDH1/2-mutated patients, complete remission achievement rate and overall survival at 2 years were similar to IDH1/2-WT patients.
Article
Oncology
Giulia Calabretto, Enrico Attardi, Carmelo Gurnari, Gianpietro Semenzato, Maria Teresa Voso, Renato Zambello
Summary: The clonal expansions of large granular lymphocytes (LGL) are frequently detected in various hematological and immune diseases. However, distinguishing between LGL leukemia (LGLL) and LGL clones is often challenging, especially in patients with unexplained cytopenias. The overlap of LGL clonal expansion with other conditions characterized by cytopenias makes their classification difficult. Recent advancements in diagnostic techniques have shed light on the relationship between LGL clones and cytopenias, paving the way for better disease classification and management approaches.
Letter
Oncology
Carmelo Gurnari, Nico Gagelmann, Anita Badbaran, Hussein Awada, Danai Dima, Simona Pagliuca, Maud D'Aveni-Piney, Enrico Attardi, Maria Teresa Voso, Raffaella Cerretti, Christine Wolschke, Marie Therese Rubio, Jaroslaw P. Maciejewski, Nicolaus Kroeger
Article
Oncology
Nelida Ines Noguera, Serena Travaglini, Stefania Scalea, Caterina Catalanotto, Anna Reale, Michele Zampieri, Alessandra Zaza, Maria Rosaria Ricciardi, Daniela Francesca Angelini, Agostino Tafuri, Tiziana Ottone, Maria Teresa Voso, Giuseppe Zardo
Summary: Acute myeloid leukemia (AML) is characterized by the expansion of clonally derived hematopoietic precursors undergoing a maturation block. The study shows that YY1, a member of the noncanonical PcG complexes, is significantly overexpressed in AML and knockdown of YY1 relieves the differentiation block in AML.
Article
Hematology
Pasquale Niscola, Carla Mazzone, Stefano Fratoni, Nicolina Rita Ardu, Laura Cesini, Marco Giovannini, Tiziana Ottone, Lucia Anemona, Maria Teresa Voso, Paolo de Fabritiis
Summary: We present a rare case of a very old patient with acute myeloid leukemia and disseminated leukemia cutis, containing an NPM1 mutation. The patient achieved a long-lasting molecular complete remission with the azacitidine/venetoclax combination therapy, highlighting its potential value in such cases.
ACTA HAEMATOLOGICA
(2023)
Article
Hematology
Gail J. Roboz, Farhad Ravandi, Andrew H. Wei, Herve Dombret, Felicitas Thol, Maria Teresa Voso, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Jianhua Zhong, C. L. Beach, Alberto Risueno, Daniel L. Menezes, Gert Ossenkoppele, Hartmut Dohner
Summary: Maintenance therapy with oral azacitidine improves overall survival and relapse-free survival in acute myeloid leukemia patients, regardless of their measurable residual disease (MRD) status at baseline.